Incyte Corp (INCY)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$94.01

Buy

$96.33

arrow-down$-0.69 (-0.72%)

Prices updated at 13 Dec 2025, 00:52 EST

Prices minimum 15 mins delay

Prices in USD

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Julian C. Baker

CEO

Mr. William Meury

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

2,617

Head office

1801 Augustine Cut-Off

Wilmington

United States

19803

+1 302 498-6700

mbooth@incyte.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Julian C. Baker Chairman of the Board	-
Mr. William Meury Director, President and Chief Executive Officer	-
Mr. Herve Hoppenot Director	1.34m
Mr. Thomas Tray Principal Financial Officer, Vice President and Chief Accounting Officer	-
Mr. Jean-Jacques Bienaime Independent Director	0.09m
Ms. Paula J. Swain Executive Vice President, Human Resources	-
Mr. Paul J. Clancy, M.B.A. Independent Director	-
Dr. Jacqualyn A. Fouse, PhD Independent Director	0.08m
Dr. Otis W. Brawley,M.D. Independent Director	0.07m
Dr. Pablo J. Cagnoni, M.D. President and Head of Research and Development	0.93m
Dr. Edmund P. Harrigan, M.D. Independent Director	-
Dr. Katherine A. High, M.D. Independent Director	0.07m
Mr. Vijay K. Iyengar Executive Vice President, Global Strategy and Corporate Development	-
Dr. Steven H. Stein, M.D. Executive Vice President and Chief Medical Officer	0.81m
Dr. Susanne Schaffert, PhD Independent Director	0.08m
Mr. Michael James Morrissey Executive Vice President and Head of Global Technical Operations	-
Ms. Sheila A Denton Executive Vice President, General Counsel and Corporate Secretary	-
Mr. Matteo Trotta Executive Vice President and General Manager, Dermatology US	-
Mr. Lee Heeson Executive Vice President, Incyte International	-
Mr. Mohamed Khairie Issa Executive Vice President and Head of US Oncology	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Baker Bros Advisors LP	30,743,663
Vanguard Group Inc	20,135,393
BlackRock Inc	17,894,297
BlackRock, Inc.	17,077,446
Dodge & Cox	13,932,416

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
31 Dec 2024	-
16 Dec 2024	-
13 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
29 Nov 2024	-
29 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
06 Nov 2024	-
02 Oct 2024	-
01 Oct 2024	-
30 Sep 2024	-
30 Sep 2024	-
12 Sep 2024	-
12 Sep 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.